Treatment of mycosis fungoides and Sezary syndrome with romidepsin: a series of 32 cases of the French Study Group for Cutaneous Lymphoma.
Fiche publication
Date publication
octobre 2018
Journal
The British journal of dermatology
Auteurs
Membres identifiés du Cancéropôle Est :
Pr AUBIN François
Tous les auteurs :
Deschamps O, Ram-Wolff C, Beylot-Barry M, Grange F, Skowron F, Dereure O, Boulinguez S, Aubin F, Ingen-Housz-Oro S, Bagot M,
Lien Pubmed
Résumé
Treatment of cutaneous T-cell lymphoma is based on skin-directed therapies for early stage disease and systemic therapies for advanced stage disease. Romidepsin (Istodax©) is a histone deacetylase inhibitor approved by the FDA, after two phase II pivotal studies for the treatment of Mycosis Fungoides (MF) and Sézary Syndrome (SS) after at least one prior line of systemic therapy . In France, romidepsin is only available on Authorization for Temporary Use. Until now, few data are available as to its use in real life. This article is protected by copyright. All rights reserved.
Référence
Br. J. Dermatol.. 2018 Oct 9;: